Achieve Life Sciences announces Mark Oki as Chief Financial Officer to enhance financial strategy and support nicotine dependence treatment development.Quiver AI SummaryAchieve Life Sciences, Inc. has...
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Akouos, Inc. (NASDAQ: AKUS) to Eli Lilly and Company is fair to Akouos shareholders. Under the terms of the transaction,...
/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Akouos, Inc. (NASDAQ: AKUS) today announced a definitive agreement for Lilly to acquire Akouos, a...
- Nonclinical data demonstrate that a single intracochlear administration of an AAVAnc80 vector led to durable restoration of auditory function and was...
- Continued progress toward planned IND submissions for AK-OTOF in the first half of 2022 and AK-antiVEGF in 2022 - Presenting new nonclinical data at...
BOSTON, May 04, 2022 (GLOBE NEWSWIRE) -- Akouos, Inc. (“Akouos”) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential...
- Advanced toward planned IND submissions for AK-OTOF in the first half of 2022 and AK-antiVEGF in 2022 - Presented data at ARO demonstrating potential of...
BOSTON, March 24, 2022 (GLOBE NEWSWIRE) -- Akouos, Inc. (“Akouos”) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential...
- Data from two nonclinical studies evaluating protein expression and tolerability support future clinical development of AK-antiVEGF for the treatment of...
BOSTON, Jan. 07, 2022 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene...
- Continued progress toward planned IND submissions for AK-OTOF in the first half of 2022 and AK-antiVEGF in 2022 - Expanded leadership team with...
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Akouos, Inc. (NASDAQ: AKUS) to Eli Lilly and Company is fair to Akouos shareholders. Under the terms of the transaction,...
/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Akouos, Inc. (NASDAQ: AKUS) today announced a definitive agreement for Lilly to acquire Akouos, a...
- Nonclinical data demonstrate that a single intracochlear administration of an AAVAnc80 vector led to durable restoration of auditory function and was...
- Continued progress toward planned IND submissions for AK-OTOF in the first half of 2022 and AK-antiVEGF in 2022 - Presenting new nonclinical data at...
BOSTON, May 04, 2022 (GLOBE NEWSWIRE) -- Akouos, Inc. (“Akouos”) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential...
- Advanced toward planned IND submissions for AK-OTOF in the first half of 2022 and AK-antiVEGF in 2022 - Presented data at ARO demonstrating potential of...
BOSTON, March 24, 2022 (GLOBE NEWSWIRE) -- Akouos, Inc. (“Akouos”) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential...
- Data from two nonclinical studies evaluating protein expression and tolerability support future clinical development of AK-antiVEGF for the treatment of...
BOSTON, Jan. 07, 2022 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene...
- Continued progress toward planned IND submissions for AK-OTOF in the first half of 2022 and AK-antiVEGF in 2022 - Expanded leadership team with...